142929-49-5

Usage

Uses

1. Used as a Crosslinker:
Acetic acid, [2-[[(1,1-dimethylethoxy)carbonyl]amino]ethoxy](9CI) is utilized as a crosslinker in various applications due to its ability to form stable amide bonds with primary amine groups when activated.
2. Used in Pharmaceutical and Biochemical Research:
In the pharmaceutical and biochemical research industries, Acetic acid, [2-[[(1,1-dimethylethoxy)carbonyl]amino]ethoxy]- (9CI) serves as a valuable tool for the synthesis of complex molecules and the study of protein-protein interactions, among other applications.
3. Used in Drug Delivery Systems:
The hydrophilic PEG spacer in Acetic acid, [2-[[(1,1-dimethylethoxy)carbonyl]amino]ethoxy](9CI) can be advantageous in drug delivery systems, potentially improving the solubility and bioavailability of therapeutic agents.
4. Used in Chemical Synthesis:
Acetic acid, [2-[[(1,1-dimethylethoxy)carbonyl]amino]ethoxy](9CI) can be employed in the synthesis of various organic molecules, taking advantage of its reactive carboxylic acid and Boc-protected amine groups.
5. Used in Material Science:
The unique properties of Acetic acid, [2-[[(1,1-dimethylethoxy)carbonyl]amino]ethoxy](9CI) may find applications in the development of new materials with specific characteristics, such as improved solubility or reactivity.

InChI:InChI=1/C9H17NO5/c1-9(2,3)15-8(13)10-4-5-14-6-7(11)12/h4-6H2,1-3H3,(H,10,13)(H,11,12)

Upstream product

• 142929-50-8 ethyl <2-<<(1,1-dimethylethoxy)carbonyl>amino>ethoxy>acetate 
• 26690-80-2 2-(N-tert-butoxycarbonylamino)ethanol 
• 24424-99-5 di-tert-butyl dicarbonate 
• 79-08-3 bromoacetic acid 
• 79-11-8 chloroacetic acid 
• 142929-48-4 1,1-dimethylethyl 3-oxo-4-morpholinecarboxylate 

Downstream Products

• 10366-71-9 2-(2-aminoethoxyl)acetic acid 
• 1351947-21-1 tert-butyl [2-(2-{[2-({5-[(2S)-1-methylpyrrolidin-2-yl]pyridin-3-yl}oxy)ethyl]amino}-2-oxoethoxy)ethyl]carbamate 
• 1351947-13-1 tert-butyl (trans-4-{[2-({5-[(2S)-1-methylpyrrolidin-2-yl]pyridin-3-yl}oxy)ethyl]carbamoyl}cyclohexyl)carbamate 
• 1351946-97-8 tert-butyl (2-{2-[(3-{5-[(2S)-1-methylpyrrolidin-2-yl]pyridin-3-yl}propyl)amino]-2-oxoethoxy}ethyl)carbamate 
• 1351946-91-2 tert-butyl {trans-4-[(3-{5-[(2S)-1-methylpyrrolidin-2-yl]pyridin-3-yl}propyl)carbamoyl]cyclohexyl}carbamate 
• 142929-63-3 2-Benzyl-2-(2-tert-butoxycarbonylamino-ethoxy)-3-phenyl-propionic acid ethyl ester 
• 142929-51-9 ethyl α-<2-<<(1,1-dimethylethoxy)carbonyl>amino>ethoxy>benzenepropanoate 

Relevant academic research and scientific papers

INHIBITORS OF SOLUBLE ADENYLYL CYCLASE

Provided are 6-amino substituted 2,6-diamino-4-choropyrimidine compounds which are specific inhibitors of soluble adenylyl cyclase. The compounds can be formulated with pharmaceutical carriers and used for reducing cyclic AMP levels. The compositions can

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

CONJUGATES COMPRISING HYDROXYALKYL STARCH AND A CYTOTOXIC AGENT AND PROCESS FOR THEIR PREPARATION

The present invention relates to a hydroxyalkyl starch conjugate and a method for preparing the same, said hydroxyalkyl starch conjugate comprising a hydroxyalkyl starch derivative and a cytotoxic agent, the cytotoxic agent comprising at least one secondary hydroxyl group, wherein the hydroxyalkyl starch is linked via said secondary hydroxyl group to the cytotoxic agent. The conjugate according to the present invention has a structure according to the following formula HAS′(-L-M)n wherein M is a residue of the cytotoxic agent, L is a linking moiety, HAS′ is the residue of the hydroxyalkyl starch derivative, and n is greater than or equal to 1, and wherein the hydroxyalkyl starch derivative has a mean molecular weight (MW) above the renal threshold.

PRODRUGS OF THERAPEUTIC COMPOUNDS

The present invention provides compounds, pharmaceutical compositions and medicaments comprising such compounds, and the use of these compounds, compositions, and medicaments in methods of treating diseases and disorders such as cancers.

Analogs of the δ opioid receptor selective cyclic peptide [2-D- penicillamine,5-D-penicillamine]-enkephalin: 2',6'-Dimethyltyrosine and Gly3-Phe4 amide bond isostere substitutions

In order to develop systemically-active opioid peptides, the δ-selective, opioid pentapeptide [D-Pen2,D-Pen5]-enkephalin (DPDPE) was modified by esterification and by substitution of 2',6'-dimethyltyrosine for tyrosine to yield 4. Co